Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index; 13 of the 14 sources its claims cite were checked for support.

Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer

Open access
Ji, Qi-lin, Zeng, Ying, Zhou, Hao, Wang, Qing-bin, Zhou, Run-ying, Zhang, Jing-jing, Wang, Xiu · 2026 · Scientific reports

Abstract

Tamoxifen (TAM) resistance remains a significant challenge in treating estrogen receptor (ER)-positive breast cancer. Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer. The lack of specific drug distribution to tumors further complicates the treatment of TAM-resistant breast cancer. Simultaneously addressing these four factors—EGFR overexpression, TAM metabolic variations, P-gp-mediated drug efflux, and poor tumor-specific delivery—can significantly enhance the treatment of TAM-resistant breast cancer. This study aimed to design a multifunctional and dual-targeting polymeric prodrug nanomicelle platform. The platform was self-assembled using the amphipathic precursor drug material [hyaluronic acid (HA)-4-hydroxytamoxifen (4-OH-TAM) ester (esterified by HA and 4-OH-TAM)] and D-α-tocopheryl polyethylene glycol succinate (TPGS), loaded with dasatinib (DAS). The nanosystem could target breast cancer mediated by HA and 4-OH-TAM, releasing DAS, 4-OH-TAM, and TPGS in tumor microenvironment. 4-OH-TAM, an active metabolite of TAM, substantially impacted TAM-resistant breast cancer by avoiding the metabolic differences in TAM. TPGS inhibited P-gp-mediated drug efflux, thereby increasing intracellular accumulation of DAS and enhancing its inhibitory effect on TAM-resistant breast cancer cells.

Overview

CoChat Summary

TL;DR

The paper reports a dual-targeting polymeric prodrug nanomicelle platform, HTT-DAS, self-assembled from HA–4-OH-TAM ester and TPGS and loaded with dasatinib, for treating tamoxifen-resistant ER-positive breast cancer. It shows pH-responsive release, CD44/ER-mediated uptake, EGFR and P-gp inhibition, and stronger in vitro and in vivo antitumor effects than free 4-OH-TAM plus DAS.

Key findings

  • HTT-DAS was optimized at an HT:TPGS mass ratio of 6:1 (particle size 182.1 ± 2.1 nm; PDI 0.19 ± 0.007) and a DAS:HTT ratio of 10:1 (drug loading 7.62 ± 0.32%; encapsulation efficiency 78.1 ± 3.32%); final HTT-DAS had size 189 ± 0.02 nm, PDI 0.22 ± 0.02, and zeta potential −20.77 ± 0.85 mV.
  • Drug release was pH-sensitive: within 48 h at pH 5.0, cumulative release of 4-OH-TAM and DAS reached (72.73 ± 3.99)% and (78.39 ± 3.09)%, respectively, versus only (35.98 ± 4.79)% and (45.3 ± 1.66)% at pH 7.4; hemolysis was <5% at 10–320 µg/mL.
  • Cellular uptake was time-dependent and dual-targeted: HTT-C6 fluorescence was stronger than TPGS-C6 and was reduced by preincubation with free HA and 4-OH-TAM; uptake was stronger in ER-positive MCF-7/TAM cells than in ER-negative MDA-MB-231 cells.
  • HTT-DAS induced an apoptosis rate of (30.73 ± 3.31)% in MCF-7/TAM cells; in vivo, tumor volume was reduced to 142 mm³, and tumor weight was 0.13 ± 0.08 g, 78.3% lower than the 4-OH-TAM + DAS group (0.60 ± 0.11 g) and 87.1% lower than the control group (1.01 ± 0.27 g), with no significant body-weight loss.
  • Western blotting showed DAS, DAS + 4-OH-TAM, and HTT-DAS reduced EGFR expression, but only HTT-DAS reduced P-gp expression in MCF-7/TAM cells; combination index values >1.15 indicated synergy for HTT-DAS at 24 h and 48 h, whereas free DAS + 4-OH-TAM was synergistic only at 48 h.

Methods

  • HTT-DAS was prepared by film dispersion from HA–4-OH-TAM ester (HT), TPGS, and DAS; characterization included DLS, TEM, zeta potential, HPLC for drug loading/encapsulation, stability in PBS and 10% FBS, pH-dependent size/PDI, dialysis release at pH 7.4, 6.0, and 5.0, and hemolysis testing.
  • In vitro studies used MCF-7/TAM (TAM-resistant, ER-positive) and MDA-MB-231 (ER-negative) cells; assays included coumarin-6 uptake by CLSM, MTT cytotoxicity, calcein-AM/PI staining, Annexin V-FITC/PI apoptosis flow cytometry, and Western blotting for EGFR and P-gp.
  • In vivo studies used female BALB/c nude mice bearing MCF-7/TAM xenografts; biodistribution was assessed with Cy5/HTT-Cy5 by IVIS, and efficacy was tested with PBS, free 4-OH-TAM + DAS, or HTT-DAS (n = 5 per group) over 11 days, followed by tumor/organ H&E, EGFR immunohistochemistry, and serum biochemistry; statistics used mean ± SD with one-way ANOVA and nonparametric tests in SPSS.

Limitations

  • The paper does not include a dedicated limitations section; it states that the mechanism by which TPGS together with DAS or 4-OH-TAM inhibits P-gp “requires further validation.”
  • Evident from the text: in vitro mechanism and efficacy were mainly tested in one TAM-resistant ER-positive cell line (MCF-7/TAM) plus one ER-negative line (MDA-MB-231), so broader applicability across resistant breast cancer models is not established.
  • Evident from the text: the in vivo efficacy study used small groups (n = 5), an 11-day treatment period, and no survival or long-term toxicity endpoints; clinical translation and comparison against TAM itself or additional controls were not reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41598-026-49617-6

Cites

30 of 31 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Scheme 1 Schematic representation of the preparation and proposed therapeutic mechanisms of HTT-DAS.
Scheme 1 Schematic representation of the preparation and proposed therapeutic mechanisms of HTT-DAS.CC BY-NC-ND · PubMed Central
Fig. 1 (A) Drug loading and encapsulation efficiency curves of DAS at different mass ratios of DAS to HTT (n = 3). (B) Malvern particle size analysis and TEM images of HTT-DAS. (C) Zeta potential measurements of DAS, HTT, and HTT-DAS. (D) Changes in HTT-DAS particle size in 7 days in PBS and 10% FBS + PBS solutions (n = 3). (E) HTT-DAS particle size and (F) PDI changes in 7 days in PBS solution at pH 5.0 (n = 3). (G) Release profiles of 4-OH-TAM and (H) DAS at pH 7.4, 6.0, and 5.0 (n = 3). (I) Hemolysis rates of HTT-DAS at various concentrations (n = 3).
Fig. 1 (A) Drug loading and encapsulation efficiency curves of DAS at different mass ratios of DAS to HTT (n = 3). (B) Malvern particle size analysis and TEM images of HTT-DAS. (C) Zeta potential measurements of DAS, HTT, and HTT-DAS. (D) Changes in HTT-DAS particle size in 7 days in PBS and 10% FBS + PBS solutions (n = 3). (E) HTT-DAS particle size and (F) PDI changes in 7 days in PBS solution at pH 5.0 (n = 3). (G) Release profiles of 4-OH-TAM and (H) DAS at pH 7.4, 6.0, and 5.0 (n = 3). (I) Hemolysis rates of HTT-DAS at various concentrations (n = 3).CC BY-NC-ND · PubMed Central
Fig. 2 (A) Confocal laser scanning microscopy (CLSM) images of MCF-7/TAM cells at 0.5, 2, and 4 h after treatment with HTT@C6. Scale bar = 100 μm. (B) CLSM images of MCF-7/TAM cells after 4 h of treatment with TPGS-C6, HTT@C6, HA + HTT@C6, and 4-OH-TAM + HTT@C6. Scale bar = 100 μm. (C) CLSM images of MCF-7/TAM and MDA-MB-231 cells following 4 h of treatment with HTT@C6. Scale bar = 20 μm.
Fig. 2 (A) Confocal laser scanning microscopy (CLSM) images of MCF-7/TAM cells at 0.5, 2, and 4 h after treatment with HTT@C6. Scale bar = 100 μm. (B) CLSM images of MCF-7/TAM cells after 4 h of treatment with TPGS-C6, HTT@C6, HA + HTT@C6, and 4-OH-TAM + HTT@C6. Scale bar = 100 μm. (C) CLSM images of MCF-7/TAM and MDA-MB-231 cells following 4 h of treatment with HTT@C6. Scale bar = 20 μm.CC BY-NC-ND · PubMed Central
Fig. 3 MTT assay of MCF-7/TAM cells subjected to different treatments for (A) 24 h and (B) 48 h (n = 3, *P < 0.05, **P < 0.01, compared with the 4-OH-TAM + DAS group). (C) Calcein-AM/PI staining images of MCF-7/TAM cells subjected to different treatments, scale bar = 200 μm. (D) Detection of MCF-7/TAM apoptosis after different treatments; (E) quantitative analysis of (D). (F) Expression levels of P-gp and EGFR in MCF-7/TAM cells subjected to different treatments (n = 3, *P < 0.05, **P < 0.01, compared with the control group); (G) quantitative analysis of (F).
Fig. 3 MTT assay of MCF-7/TAM cells subjected to different treatments for (A) 24 h and (B) 48 h (n = 3, *P < 0.05, **P < 0.01, compared with the 4-OH-TAM + DAS group). (C) Calcein-AM/PI staining images of MCF-7/TAM cells subjected to different treatments, scale bar = 200 μm. (D) Detection of MCF-7/TAM apoptosis after different treatments; (E) quantitative analysis of (D). (F) Expression levels of P-gp and EGFR in MCF-7/TAM cells subjected to different treatments (n = 3, *P < 0.05, **P < 0.01, compared with the control group); (G) quantitative analysis of (F).CC BY-NC-ND · PubMed Central
Fig. 4 (A) Fluorescence imaging of MCF-7/TAM tumor-bearing nude mice after intravenous injection of HTT-CY5 or CY5 and ex vivo fluorescence images (H: heart; L: liver; S: spleen; Lu: lung; K: kidney; T: tumor). (B) Semi-quantitative analysis of ex vivo fluorescence images (n = 3, ***P < 0.001). (C) Schematic illustration of the in vivo treatment procedure in mice. (D) Tumor-growth-inhibitory effects of different treatments. (E) Tumor size in each mouse after various treatments. (F) Images of excised tumors in each group. (G) Quantitative analysis of tumor mass after treatments (n = 5, *P < 0.05, **P < 0.01, ***P < 0.001). (H) Changes in body weight of mice during treatments.
Fig. 4 (A) Fluorescence imaging of MCF-7/TAM tumor-bearing nude mice after intravenous injection of HTT-CY5 or CY5 and ex vivo fluorescence images (H: heart; L: liver; S: spleen; Lu: lung; K: kidney; T: tumor). (B) Semi-quantitative analysis of ex vivo fluorescence images (n = 3, ***P < 0.001). (C) Schematic illustration of the in vivo treatment procedure in mice. (D) Tumor-growth-inhibitory effects of different treatments. (E) Tumor size in each mouse after various treatments. (F) Images of excised tumors in each group. (G) Quantitative analysis of tumor mass after treatments (n = 5, *P < 0.05, **P < 0.01, ***P < 0.001). (H) Changes in body weight of mice during treatments.CC BY-NC-ND · PubMed Central
Fig. 5 (A) H&E and EGFR immunofluorescence staining of tumor tissues after treatments. Scale bar = 100 μm. (B) Analysis of the serum levels of alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (CRE), and aspartate aminotransferase (AST) in mice after treatments. (C) H&E staining of the heart, liver, spleen, lung, and kidney tissues from mice following various treatments. Scale bar = 200 μm.
Fig. 5 (A) H&E and EGFR immunofluorescence staining of tumor tissues after treatments. Scale bar = 100 μm. (B) Analysis of the serum levels of alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (CRE), and aspartate aminotransferase (AST) in mice after treatments. (C) H&E staining of the heart, liver, spleen, lung, and kidney tissues from mice following various treatments. Scale bar = 200 μm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 0 Not checked · 92 Own results and interpretations

68 more claims · 2 with their cited sources checked

Create a free account to see all 100 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Zhang, H. et al. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp). Med. Res. Rev. 41, 525–555 (2021). · DOI · Paper page

Metadata

Authors
Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X.
Affiliations
Bengbu Medical College (CN)
Corresponding author
  • Zhang, Jing-jing
  • Wang, Xiu
Venue
Scientific reports
Published
2026-04-26
Volume
16
Issue
1
ISSN
2045-2322 (ISSN-L)
OpenAlex
W7155683242
Cited by
1
References
31
Citations by year
2026: 1
FWCI
1.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
tamoxifen resistance, estrogen receptor-positive breast cancer, hyaluronic acid, 4-hydroxytamoxifen, dasatinib, TPGS, P-glycoprotein inhibition, EGFR overexpression, pH-responsive drug release, anticancer drug delivery, tamoxifen metabolism
MeSH terms
Dasatinib, Animals, Breast Neoplasms, Female, Humans, Hyaluronic Acid, Micelles, Polymers, Prodrugs, Tamoxifen, Vitamin E, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Nanoparticles, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer. https://app.cochat.ai/papers/10.1038/s41598-026-49617-6
The paper
Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X. (2026). Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer. Scientific reports. https://doi.org/10.1038/s41598-026-49617-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.